Skip to main content

Treatment Clinical Trials for Glioblastoma

Review the glioblastoma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 106

DB107-RRV in Combination with DB107-FC for the Treatment of Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
Status: Active
Location: 3 locations
Liposomal Rhenium Re 186 in Treating Patients with Recurrent Glioblastoma
Status: Active
Location: 3 locations
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Status: Active
Location: 3 locations
Troriluzole for the Treatment of Recurrent IDH Wild Type Glioblastoma
Status: Active
Location: 3 locations
WP1066 and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Location: 2 locations
A Study with L19TNF in Combination with Lomustine in Patients with Glioblastoma At Progression or Recurrence
Status: Active
Location: 2 locations
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Status: Active
Location: 4 locations
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Status: Active
Location: 2 locations
At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls
Status: Active
Location: 2 locations
A Vaccine (RNA-LP) for the Treatment of Recurrent Pediatric High-Grade Glioma and Recurrent Osteosarcoma, RNA PRIME Trial
Status: Active
Location: 2 locations
Intra-arterial Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treating Patients Under 22 Years of Age with Relapsed or Refractory Intracranial Glioma
Status: Active
Location: 2 locations
Intracavitary Administration of 15.GPC3-CAR T Cells for the Treatment of Patients with GPC3-Positive Recurrent Glioblastoma who are Undergoing Repeat Resection, GO-CART Trial
Status: Active
Location: 2 locations
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Status: Active
Location: 2 locations
Vaccine Therapy, Radiation Therapy, Pembrolizumab, and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma or Personalized Neoantigen Vaccine for Progressive/Recurrent Low-Grade Glioma
Status: Active
Location: 2 locations
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Status: Active
Location: 2 locations
Efineptakin alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
G-CSF Following Standard Chemoradiation in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Botensilimab, Balstilimab, and Liposomal Doxorubicin in Combination with Ultrasound-Mediated Blood Brain Barrier Opening for the Treatment of Patients with Newly Diagnosed Glioblastoma
Status: Active
Location: Northwestern University, Chicago, Illinois
Escitalopram in Treating Cognitive Dysfunction in Patients with Grade IV Glioma and Grade III Astrocytoma
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Methimazole for the Treatment of Patients with Glioblastoma
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Optune GIO with MRI-Guided Laser Ablation Surgery and Pembrolizumab for the Treatment of Progressive or Recurrent Glioblastoma, OPTIMUS PRIME Trial
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Engineered Cells (P140K MGMT Hematopoietic Stem Cells), O6-Benzylguanine, Temozolomide, and Carmustine for the Treatment of Resected Supratentorial Glioblastoma or Gliosarcoma
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Lerapolturev versus Lomustine for the Treatment of Recurrent GBM
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas